The under-use of aspirin for secondary prophylaxis of vascular events

Abstract

Get full access to this article

View all access options for this article.

References

Morgan

. Ethical aspects in relation to aspirin prophylaxis. Quality in Primary Care, 2008: 16(6): 433–40.

Sung

Lau

Ching

Lee

Chiu

. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: A randomized trial. Annals of Internal Medicine, 2010: 152: 1–9.

Luis

A García Rodríguez

. Discontinuation of low dose aspirin and risk of myocardial infarction: Case-control study in UK primary care. BMJ, 2011: 343: d4094. doi: 10.1136/bmj.d4094.

Zaninelli

Kaufholz

Schwappach

. Physicians’ attitudes toward post-MI aspirin prophylaxis: Findings from an online questionnaire in Europe and Latin America. Postgraduate Medicine, 2009: 121: 44–53.

Elwood

Hughes

Morgan

Brown

Longley

. A survey of aspirin prophylaxis in Wales. Quality in Primary Care, 2005: 119: 734–37.

Elwood

Morgan

White

. Aspirin taking in a south Wales county. British Journal of Cardiology, 2011: 18: 238–40.

Antithrombotic Trialists’ Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomized trials. The Lancet, 2009: 373: 1849–690.

Morgan

. Policy development and implementation: The National Service Framework for Older People in Wales. Eurohealth, 2010: 15(4): 23–25.

Rothwell

. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet, 2010: 376: 1741–50.

10.

Morgan

. The potential contribution of aspirin to healthy ageing. Age & Ageing, 2011. doi: 10.1093/ageing/afr139.